Liquidia Corporation announced that it has entered into a securities purchase agreement to issue 7,182,532 common shares at a price of $10.442 per share for the gross proceeds of $74,999,999 on January 4, 2024. The transaction will include participation from new investor, fund managed by, Patient Square Capital, LP. The transaction is expected to close on January 8, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.53 USD | +1.29% | -5.72% | +4.16% |
Apr. 01 | Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension | MT |
Apr. 01 | Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.16% | 953M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- LQDA Stock
- News Liquidia Corporation
- Liquidia Corporation announced that it expects to receive $74.999999 million in funding from Patient Square Capital, LP